News & Updates

Show Multimedia Only

Original New Drug Application Approvals by US FDA (16-31 October 2023)

08 Nov 2023

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

08 Nov 2023

Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer

08 Nov 2023 by

In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).

08 Nov 2023

Placebo effect delivers in open-angle glaucoma

07 Nov 2023

Treatment with placebo is successful in patients with open-angle glaucoma or ocular hypertension, achieving lower intraocular pressure (IOP), compared with untreated control participants, reports a recent study.

07 Nov 2023

Rosuvastatin on par with atorvastatin in CAD

06 Nov 2023 by

Rosuvastatin is as effective as atorvastatin for the composite outcome of all-cause death, myocardial infarction (MI), stroke, or any coronary revascularization at 3 years in adults with coronary artery disease (CAD), according to the secondary analysis of the LODESTAR trial.

06 Nov 2023

Selpercatinib superior to standard MKIs for rare thyroid cancer

06 Nov 2023 by

Selpercatinib, a highly selective and potent RET inhibitor, trumped two multikinase inhibitors (MKIs) – cabozantinib and vandetanib – for the treatment of advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (MTC) in the first-line (1L) setting, according to the interim analysis results of the phase III LIBRETTO-531 trial.

06 Nov 2023

Which DOAC is best for gastrointestinal haemorrhage in atrial fibrillation patients?

05 Nov 2023

Use of apixaban appears to reduce the risk of gastrointestinal haemorrhage (GIH) compared with dabigatran, rivaroxaban, and vitamin K antagonist (VKA) in patients with nonvalvular atrial fibrillation, a recent study has shown. On the other hand, rivaroxaban use tends to increase GIH risk relative to dabigatran and VKA.

05 Nov 2023

Add-on immunotherapy prolongs survival in advanced endometrial cancer

03 Nov 2023 by

In the treatment of patients with advanced or recurrent endometrial carcinoma, adding the PD-L1 inhibitor atezolizumab to chemotherapy helps lower the risk of progression or death, according to the phase III AtTEnd trial.